Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930539 | 0.88 | TLR7 (0.41) | KDM4EFAAH | |
| SCHEMBL6838678 | 0.85 | KDM4E (0.43) | HPGDSCKS1BSKP1SKP2KDM4E | |
| SCHEMBL6833883 | 0.84 | KDM4E (0.42) | HPGDSCKS1BSKP1SKP2KDM4E | |
| SCHEMBL6838661 | 0.83 | CETP (0.42) | HPGDSCKS1BSKP1SKP2KDM4E | |
| SCHEMBL6925924 | 0.79 | GPR119 (0.44) | HPGDSKDM4EPKMGBA1GPR119 | |
| SCHEMBL6925928 | 0.78 | TP53 (0.49) | KDM4ELMNATDP1TP53THRB | |
| SCHEMBL3816260 | 0.76 | CKS1B (0.45) | CKS1BSKP1SKP2GBA1FAAH | |
| SCHEMBL6928550 | 0.75 | PTGER4 (0.40) | KDM4E | |
| SCHEMBL6923675 | 0.74 | TLR7 (0.53) | KDM4EPKMGPR119LMNA | |
| SCHEMBL6927078 | 0.74 | KDM4E (0.45) | KDM4EPKMGPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | HPGDS 299/4885CKS1B 154/4885SKP1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.